Line Schmidt Tarpgaard

Medicin og biovidenskab

1. Oxaliplatin 100%
2. Colorectal Neoplasms 93%
3. Cetuximab 41%
4. Irinotecan 36%
5. Aerosols 32%
6. Drug Therapy 27%
7. Bevacizumab 22%
8. Capecitabine 21%
9. encorafenib 19%
10. MEK162 18%
11. MicroRNAs 16%
12. Neoplasms 15%
13. Type I DNA Topoisomerase 14%
14. Survival 14%
15. pembrolizumab 14%
16. Urokinase Plasminogen Activator Receptors 13%
17. Cell Line 12%
18. Epirubicin 12%
19. Therapeutics 12%
20. Biomarkers 12%
21. Neoplasm Metastasis 12%
22. XELOX 12%
23. Tissue Inhibitor of Metalloproteinase-1 11%
24. Gene Amplification 11%
25. Safety 11%
26. Urokinase-Type Plasminogen Activator 11%
27. Colonic Neoplasms 11%
28. Neoplasm Genes 10%
29. Pandemics 10%
30. Group Psychotherapy 10%
31. Gastrectomy 10%
32. DNA Methylation 9%
33. Epidermal Growth Factor 9%
34. Stomach Neoplasms 9%
35. Adenocarcinoma 9%
36. Drug Resistance 9%
37. Progression-Free Survival 8%
38. ErbB Receptors 7%
39. Quality of Life 7%
40. Phenotype 7%
41. Recurrence 7%
42. Biopsy 6%
43. Cross-Sectional Studies 6%
44. Angiogenesis Inhibitors 6%
45. Genes 5%
46. Multivariate Analysis 5%
47. hydrogen sulfite 5%